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AbstrACt
Introduction Hypertension is a leading contributor to 
the global burden of disease. While safe and effective 
treatment exists, blood pressure control is poor in many 
countries, often reflecting barriers at the levels of health 
systems and services as well as at the broader level of 
patients’ sociocultural contexts. This study examines how 
these interact to facilitate or hinder hypertension control, 
taking into account characteristics of service provision 
components and social contexts.
Methods and analysis The study, set in Malaysia and 
the Philippines, builds on two systematic reviews of 
barriers to effective hypertension management. People 
with hypertension (pre-existing and newly diagnosed) will 
be identified in poor households in 24–30 communities 
per country. Quantitative and qualitative methods will be 
used to examine their experiences of and pathways into 
seeking and obtaining care. These include two waves of 
household surveys of 20–25 participants per community 
12–18 months apart, microcosting exercises to assess 
the cost of illness (including costs due to health seeking 
activities and inability to work (5 per community)), 
preliminary and follow-up in-depth interviews and digital 
diaries with hypertensive adults over the course of a 
year (40 per country, employing an innovative mobile 
phone technology), focus group discussions with study 
participants and structured assessments of health facilities 
(including formal and informal providers).
Ethics and dissemination Ethical approval has been 
granted by the Observational Research Ethics Committee 
at the London School of Hygiene and Tropical Medicine 
and the Research Ethics Boards at the Universiti Putra 
Malaysia and the University of the Philippines Manila. 
The project team will disseminate findings and engage 
with a wide range of stakeholders to promote uptake 
and impact. Alongside publications in high-impact 
journals, dissemination activities include a comprehensive 
stakeholder analysis, engagement with traditional and 
social media and ‘digital stories’ coproduced with research 
participants.
bACkground 
Control of hypertension is an essential part of 
any strategy to reduce the burden of cardiovas-
cular diseases (CVDs) worldwide.1 2 Malaysia 
and the Philippines are countries where 
hypertension control is poor (table 1), and 
many other low-income and middle-income 
countries (LMICs) face similar challenges.3 4 
The poorest individuals in the lowest wealth 
quintile are especially disadvantaged,4–7 with 
strengths and limitations of this study
 ► Our prospective cohort design study benefits from 
a solid evidence base consisting of two systematic 
reviews.
 ► A key strength of the proposed study is its 
mixed-method design including innovative mobile 
phone technology to enhance examination of patient 
pathways.
 ► We may encounter limited access to facilities, as 
facility staff may be reluctant to participate or fully 
disclose information due to regulatory or commer-
cial reasons.
 ► Participant attrition between the interview and fol-
low-up interview and household survey phases may 
constitute a limitation to findings inferred from fol-
low-up data.
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profound implications for their health and economic 
well-being.8 As two recent systematic reviews showed, 
health systems and services barriers to effective manage-
ment exist in countries at all levels of development but 
can be overcome.9 10 However, a comprehensive approach 
will also take account of patients’ sociocultural contexts, 
exploring how they interact with health services to facili-
tate or hinder hypertension control.
The core elements of hypertension management are 
well established, set out in the World Heart Federation 
Hypertension Roadmap and other guidelines for low-re-
source settings.8 11 However, their specific application 
in each country must take account of the lived experi-
ences of those with hypertension and frontline health-
care providers, exploring understanding of the condition 
and treatment, actual sociocultural barriers to obtaining 
and adhering to treatment and how barriers can be over-
come. Our previous research in Malaysia and Colombia 
demonstrated the importance of local context.12 13 Thus, 
the first objective of the Responsive and Equitable Health 
Systems— Partnership on Non-Communicable Diseases 
(RESPOND) project is to produce robust evidence on 
the barriers to effective hypertension management (ie, 
at diagnosis, treatment initiation and adherence and ulti-
mately control) faced by poor households in Malaysia and 
the Philippines. This will be achieved through quantita-
tive and qualitative observational methods in a longitu-
dinal study design.
The experience of living with and managing hyper-
tension is a dynamic process shaped by health services 
and people’s social contexts and life circumstances.13–16 
Non-intrusive methods are needed to capture patients’ 
perspectives of the changing complexities of seeking care 
over time. Thus, our second objective is to evaluate oppor-
tunities offered by mobile phone technology to study the 
lived experience of hypertension and barriers people face 
in handling hypertension. Specifically, we will develop an 
innovative qualitative data collection method involving 
the use of real-time ‘digital diaries’ in both countries.
MEthods And study dEsIgn
This is a prospective cohort design combining three quan-
titative and three qualitative elements to explore several 
research questions: How are patients with hypertension 
diagnosed? What pathways do patients follow through the 
key stages of care? What care is sought and received, and 
what are the economic and social costs? How does this 
differ by patient characteristic, and why? What barriers 
impede continuing access to care and medication? How 
does context affect experiences of care? How feasible and 
acceptable are ‘digital diaries’ for collecting longitudinal 
qualitative data on lived experiences with chronic illness?
In each country, the quantitative elements include: 
(A) 600 initial and follow-up household surveys (12–18 
months apart) of patients with hypertension residing 
in 24–30 low-income rural and urban communities, 
(B) an embedded microcosting study of 5 hypertensive 
participants in each community and (C) approximately 
200 structured facility assessments of hypertension care 
providers. The qualitative components are: (D) 40 initial 
and follow-up in-depth semistructured interviews among 
a subsample of survey participants with (E) up to 40 digital 
diaries recorded by interviewees between interviews and 
(F) 12 focus group discussions (FGDs) with hypertensive 
adults in 6 different communities. These elements are 
illustrated in figure 1.
Initial and follow-up household surveys
In each country, 24–30 communities (mukim in Malaysia 
and barangays in the Philippines) will be selected, divided 
between urban and rural areas. In Malaysia, communities 
are in four peninsular states (Selangor, Kelantan, Perak 
and Johor). In the Philippines, 7 urban communities are 
in the City of Valenzuela in Metro Manila and 8 urban 
and 15 rural communities in Quezon province. While 
these have been purposefully selected to facilitate access 
by researchers, we will randomly select adults living within 
poor households (low-income households qualifying for 
government subsides under the BR1M programme in 
Malaysia17 and the 4P programme in the Philippines18) to 
obtain a statistically representative sample.
Within selected households, eligible individuals are: 
(1) aged 35–70 years at screening, (2) living within house-
holds expected to remain at the current address/loca-
tion for at least 18 months and (3) either a self-reported 
history of hypertension or identified as hypertensive 
during screening. Individuals with a self-reported history 
of either cancer and/or HIV will be excluded, as their 
healthcare use is likely to be atypical.
After informed consent is taken, recruited participants’ 
blood pressure measurement will be taken using a digital 
sphygmomanometer following a standardised procedure. 
Hypertension is defined as blood pressure greater than 
Table 1 Treatment gap in hypertension among adults aged 35–70
Country
Hypertension 
prevalence
% aware 
hypertensives
% of treated 
hypertensives
% of controlled 
hypertensives
% treated in 
wealthiest quintile
% treated in 
poorest quintile
Canada 
(comparator)
37.5 55.2 54.0 24.8 51.8 55.6
Malaysia 46.6 48.1 41.2 12.5 41.5 36.6
Philippines 51.2 54.5 46.1 13.5 64.5 34.1
Source: PURE Study.4
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or equal to 140/90 mm Hg or a self-reported history of 
hypertension.19 Among all hypertensive members in 
eligible households, one will be invited to participate 
using a probability based method, such as the KISH, 
age-order or full enumeration methods.20
A questionnaire consisting of validated instruments, 
including the Demographic & Health Surveys,21 WHO 
STEPS,22 World Values Survey23 and the Living Condi-
tions, Lifestyle and Health Survey,24 will be administered 
to participants within their homes, collecting information 
on housing characteristics, including structure, amenities 
and household assets. A validated household asset-based 
wealth score, allowing within-country and cross-country 
comparisons, will be calculated.25 26 Detailed informa-
tion from individuals and households will be collected, 
including age, gender, marital status, ethnicity, educa-
tion, literacy, occupation; hypertension-related care 
experiences in the past 12 months (including service 
utilisation, settings (formal and informal practitioners, 
including criteria for choosing), treatment and adher-
ence, transportation to care, knowledge of hypertension, 
attitudes to hypertension and its treatment); personal 
and environmental tobacco exposure; socioeconomic 
factors including employment income, education and 
psychosocial factors (social capital, attitudes and beliefs) 
and modifiable CVD risk factors for the ‘non-laboratory’ 
INTERHEART risk score.27 Data on healthcare pathways 
will be subdivided into discrete stages along the journey, 
collecting details of experiences at each, including dura-
tion, location, processes undertaken, treatment provided, 
costs and self-reported reasons for seeking care.28 A 
second wave of interviews, using an adapted version of 
the first instrument, will be conducted on the same partic-
ipants after 12 months.
Sample size calculation took account of many possible 
analyses. For example, the ability to detect an urban-rural 
difference in treatment of hypertension in a middle-in-
come country with α=0.05 and power of 0.8 (two-tailed), 
which one recent study suggested was as large as 13 
percentage points (42% urban, 28% rural),3 would 
require a sample of 364 individuals with hypertension.
Microcosting study
The microcosting study assesses the economic burden 
of hypertension on poor households. All who consent 
to participate in the household survey and are aware of 
their hypertension at baseline will be eligible to partici-
pate. Five in each community will be selected randomly to 
provide microcosting data. They will be asked additional 
questions related to household income and expenditure, 
health expenditure related to hypertension manage-
ment, health financing (including insurance coverage) 
and coping strategies (labour substitution for ill person 
and/or caretaker, use of savings, changing consumption 
patterns, sale of assets, borrowing, other strategies). If 
participants cannot provide the requested information 
(eg, because they are not involved in the management 
of household finances), they will be asked to consult a 
knowledgeable household member. The same informa-
tion will be collected at baseline and follow-up.
Facilities assessment
Health system assessments will be undertaken contempo-
raneously with the second round of household surveys. 
Figure 1 Study elements in Malaysia and the Philippines over 18 months.
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These will provide ‘focused snapshots’ of the hyperten-
sion care available to communities. Facilities included are 
those where patients receive care for hypertension within 
the six communities in both countries where FGDs will be 
conducted (see below). They will be identified according 
to participant-led utility of healthcare providers, encom-
passing different levels of public, private, not-for-profit 
hospitals and clinics, complementary care providers, 
traditional and alternative healers, community health 
workers, outreach programmes/missions, retail pharma-
cies, drug stores or dispensaries, general retailers and/
or mobile vendors. Within each of the 6 communities in 
both countries, a minimum of 2–3 providers of each type 
within the community will be included, generating up to 
200 assessments across a very diverse range of providers.
Trained data collectors will use a structured facility 
questionnaire informed by the Service Availability and 
Readiness Assessments (SARA) developed by the WHO29 
to characterise care in selected facilities, including infra-
structure and work conditions; human resources; equip-
ment, medicines and supplies; written information and 
educational materials.30 Questionnaires will also examine 
providers’ practices, perspectives and experiences and 
provide space for data collectors to provide free text 
information on their impressions and comments on the 
respondent, facility and any other observations.
In-depth qualitative interviews
Initial and follow-up in-depth qualitative interviews will 
be conducted with a total of 80 participants (40 each in 
Malaysia and the Philippines). These will be purposively 
sampled from the household survey participants. The 
local teams will seek to recruit a balanced sample by sex, 
age, stage of treatment process, rural-urban locality and 
health complexity. Each participant will be interviewed 
shortly after completion of the household survey and 
again after 12–18 months have passed. Interviews will 
be conducted by the local research team and will be 
audio-recorded and transcribed verbatim for analysis. 
Information about hypertension services will be provided 
to all participants after the interview.
The interview will be conversational and explore partic-
ipants’ views on hypertension, including treatment and 
care, as well as their own personal experiences of living 
with the condition and of accessing and using various 
types of healthcare services, including traditional and 
complementary medicine. We will attempt to understand 
people’s conception of hypertension (including its diag-
nosis and treatment) and lived healthcare experiences 
and trajectories in relation to their wider sociocultural 
and environmental contexts (eg, work, community and 
family relationships). Follow-up interviews will explore 
changes over time and issues raised in the first inter-
view and during digital diary recording (see below). To 
address our secondary methodological objective, we will 
add additional questions for those who have completed 
digital diaries in order to explore their experiences of 
using the mobile-phone diary technology and to assess 
the overall feasibility of this qualitative data collection 
method.
digital diaries
All interview participants will be invited to complete 
optional digital diaries (via mobile phones) between the 
initial and follow-up interviews, yielding a maximum of 
80 digital diaries from both countries. Those who consent 
but do not have a mobile phone will be provided with one 
(along with mobile phone credit) from the study team 
to allow the recording of their digital diary. Those who 
already possess mobile phones will only receive mobile 
phone credit. The participants will be trained on how 
to submit diary entries, provided with a guidance leaflet 
to keep after the training and continually engaged for 
in-depth information on patient experience.
Diary participants will be encouraged to record their 
experiences of living with hypertension, the barriers to 
treatment and control of hypertension they and their 
families face and, crucially, their view of feasible solu-
tions. Participants will be able to submit audio (spoken), 
written (text messages) and visual (photo, video) material 
via mobile phones. Study team members will explain to 
participants that diary recording is totally voluntary and 
that they can record as much as they prefer. They will also 
discuss with them whether they would be happy to receive 
probes via text message from study members in some occa-
sions. Through such probing, respondents can reflect on 
and reappraise their own experiences with hypertension 
and use of services and thus improve the depth of the 
data. If participants do not submit any entries in the first 
2 months of enrolling into the study, they will be replaced 
with another participant.31
Focus group discussions
Twelve FGDs with study participants will be held after the 
follow-up interviews have been completed, comprising 
six each from the Philippines and Malaysia. We aim for 
between 7 and 10 participants per FGD, yielding a total 
FGD sample between 84 and 120. At least one FGD will be 
conducted exclusively with participants who completed 
digital diaries. The study team will strive to match indi-
viduals with other FGD participants by age group and sex.
The focus groups offer an opportunity to access shared 
and conflicting aspects of the participant’s health beliefs 
and experiences and social processes that shape individual 
decision-making about treatment, accessing services and 
so on. The discussion will focus on trajectories of care and 
participants’ own prioritisation of issues and solutions.
Patient and public involvement
The development of our research questions and study 
design was based on the premise that effective manage-
ment of hypertension requires patient-centred health 
systems that respond to patient needs, health seeking 
behaviour and preferences, which often vary among and 
within countries. We have engaged with stakeholders and 
community representatives, including patient groups, 
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during the project inception phase to identify major chal-
lenges faced by the poor and hard-to-reach communities, 
and to understand local culture and how it may affect 
the study. We will maintain this engagement throughout 
field work and analysis to ensure that we can respond 
to emerging changes in the field and allow adaptation 
in real time. In line with our patient-centred approach, 
several key outputs will be coproduced jointly between 
communities and researchers. Some of these outputs 
were designed explicitly to engage the public through 
digital stories, policy briefings, webcasts and interactive 
panels.
AnAlysIs
Quantitative components
To describe pathways of care, we will draw on methods 
used previously to examine the unique sequences of care-
seeking behaviours taken by hypertensive individuals 
to manage their condition.28 The resulting data will be 
used to analyse the determinants of hypertension detec-
tion, treatment and control using appropriate regression 
models. We will also use multilevel models that nest the 
experience of the individual within their community and 
health systems contexts, to obtain community-adjusted 
estimates.
The household economic burden of hypertension 
will be assessed by summing all direct and indirect costs 
incurred by households related to hypertension over the 
preceding 12 months. Indirect costs will be estimated 
using the human capital model,32 accounting for lost 
productivity due to morbidity and premature mortality. 
Morbidity costs are defined as lost income due to disability 
and inability to work as a result of hypertension and/or its 
consequences, calculated by multiplying total of days off 
work by a context-appropriate valuation of average gross 
daily earnings. Mortality costs are defined as lost income 
attributable to hypertension-related premature mortality, 
multiplying years of life lost by a context-appropriate 
valuation of annual net income. Years of life lost will be 
calculated using the Global Burden of Disease methods.33 
Catastrophic health payment will be defined as occurring 
when health expenditures exceed 40% of a household’s 
non-food expenditures or capacity to pay for services, in 
the 12 months prior to the interview; a range of thresh-
olds will be used for sensitivity analyses.
Qualitative components
Analysis of qualitative data generated via interviews, digital 
diaries and FGDs will be conducted by local researchers 
with support by the London team. The analysis will focus 
on how participants (and carers) make sense of hyper-
tension and the experience of living with and managing 
the condition and accessing care. It will also examine the 
temporal ordering of events in care seeking and manage-
ment of hypertension, to understand links between 
actions and consequences over time and across contexts. 
A combined deductive and inductive approach will guide 
the analysis,34 with the process reviewed and refined itera-
tively. A coding framework will be developed using Nvivo 
11 qualitative analysis software, followed by an analyt-
ical process of identifying, comparing and contrasting 
increasingly abstract themes, within and across countries.
data management
All digital data will be anonymised and transferred to 
secure servers. The data will be accessible to project 
members in the UK, Malaysia and the Philippines 
via LSHTM’s secure/password protected web portal. 
User authentication and encryption will be applied 
throughout. Laptops and data sticks used in data collec-
tion will be encrypted, and institutional networks are 
protected using user authentication. Any printed mate-
rial used during transcription will be stored in a locked 
cabinet and destroyed when no longer needed.
dissemination
Our knowledge dissemination strategy includes publica-
tion of academic articles in high-impact journals, engage-
ment with key stakeholders informed by a stakeholder 
analysis and contributions to traditional and social media.
dIsCussIon
The RESPOND project is particularly appropriate to 
assess the health needs of poor populations in Malaysia 
and the Philippines. The economic and treatment burden 
of hypertension is likely to disproportionately affect 
poor populations who suffer multiple disadvantage and 
substantial disease burden, both infectious and non-com-
municable. Means to address this issue, and the growing 
non-communicable disease (NCD) burden more broadly, 
is now an important policy priority. Evidence from the 
RESPOND study will promote essential insights to design 
and implement contextually appropriate initiatives.
While many of the findings from the RESPOND project 
will be specific to the two countries, some will be more 
widely applicable. The project will also inform the devel-
opment of methods that can be used in other LMICs at a 
similar stage of the epidemiological transition, with rela-
tively under-resourced health systems where patient-cen-
tred approaches focused on the needs of the poor can 
be further enhanced. This is facilitated by our framing of 
the research questions and design within the global litera-
ture on NCD, ensuring possibilities for comparisons with 
other settings, supporting exposure of the researchers 
involved to international debates and engagement with 
dissemination activities at global and national levels.
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